Hemophilia A – Pipeline Review, H2 2018
- Pages: 186
- Published: November 2018
- Report Code: GMDHC11006IDB
Global Markets Direct’s, ‘Hemophilia A – Pipeline Review, H2 2018’, provides an overview of the Hemophilia A pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hemophilia A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Hemophilia A
– The report reviews pipeline therapeutics for Hemophilia A by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Hemophilia A therapeutics and enlists all their major and minor projects
– The report assesses Hemophilia A therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Hemophilia A
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hemophilia A
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hemophilia A pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Amarna Therapeutics BV
Apitope International NV
Bayer AG
Beijing Tiantan Biological Products Co Ltd
BioMarin Pharmaceutical Inc
Bioverativ Inc
Casebia Therapeutics
Catalyst Biosciences Inc
Chugai Pharmaceutical Co Ltd
CSL Ltd
Daiichi Sankyo Co Ltd
DBV Technologies SA
EpiVax Inc
Expression Therapeutics LLC
GC Pharma
ID Pharma Co Ltd
Idogen AB
Immusoft Corp
Innovare R & D SA De CV
LFB SA
Novo Nordisk AS
Octapharma AG
Okklo Life Sciences BV
OPKO Biologics Ltd
Pangen Biotech Inc.
Pfizer Inc
Pharming Group NV
Promethera Biosciences SA
Recursion Pharmaceuticals Inc
Sangamo Therapeutics Inc
Sanofi
Shire Plc
Sino Biopharmaceutical Ltd
SK Chemicals Co Ltd
Spark Therapeutics Inc
Ultragenyx Pharmaceutical Inc
UniQure NV
XL-protein GmbH
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.